Previous 10 | Next 10 |
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the approval of ...
The following healthcare companies have filed for mixed shelf offerings: More news on: Cytokinetics, Incorporated, Twist Bioscience Corporation, Axonics Modulation Technologies, Inc., Healthcare stocks news, Read more ...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices, today announced that it will release financial results for the third quarter and first nine mont...
Believes Claims are Without Merit and an Attempt to Suppress Innovation and Competition Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing sacral neuromodulation (“SNM”) devices, today announced th...
Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating at Piper Jaffray. More news on: Axonics Modulation Technologies, Inc., Homology Medicines, Inc., Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating and $43 (110% upside) price target at Barclays. More news on: Axonics Modulation Technologies, Inc., GW Pharmaceuticals plc, ShockWave Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more...
Approximately 300 Physicians Registered to Attend Axonics-sponsored Seminars Showcasing Recently FDA-Approved 1 Axonics r-SNM ® System First Commercial Implants in the U.S. Planned for the Week of October 28 Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a med...
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) system, today announced it achieved two milestones that expand its commercial reach in Fran...
Durable Outcomes Highlighted in Plenary Session Presentation; Expanding on Positive Topline Data Released in August More than 350 Physicians Attended a Symposium Highlighting Hands-on Physician Experience with the Recently FDA-Approved Axonics r- SNM ® System 1 Axonics Mod...
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device, today announced that it has entered into an exclusive agreement to supply the Axoni...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...